Tenet Health (THC)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$265.05+0.59%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · THC
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $265 THC trades at 14× p/e, below its 23× p/e peer median. Our $442 fair value sits well above the price. We hold it with low confidence: our number sits well above the analyst range and the peer anchor overstates how cheap it looks. Analysts target $231–$308. Note: our $442 fair value sits above the entire analyst range ($231–$308). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $283.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $1614.90 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $2471.25 | — | — | Hist. CAGR | high |
| graham number | 12M | $184.34 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$231.00 – $308.00 (median $283.00) · 15 analysts · as of 2026-08-14
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $226.53 |
| 5.6 |
| 64.06 |
| TTM |
| high |
| Peer P/FCF | 12M | $607.89 | 16.9 | 36.00 | TTM | high |
| Peer P/E | 12M | $448.65 | 23.2 | 19.34 | TTM | high |
| Peer P/S | 12M | $278.55 | 1.1 | 259.78 | TTM | high |
| PEG | 12M | $190.35 | 9.8 | 19.34 | TTM | high |
| residual income | 12M | $128.24 | — | — | TTM | high |
| Own P/E history | 12M | $221.80 | 11.5 | 19.34 | TTM | high |
| triangulated | 12M | $499.84 | 23.2 | 21.55 | Triangulated | high |
| Peer P/FCF | 3Y | $924.52 | 16.9 | 54.76 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $728.08 | 23.2 | 31.39 | Analyst | medium |
| Peer P/S | 3Y | $288.37 | 1.1 | 268.94 | guidance | medium |
| PEG | 3Y | $308.90 | 9.8 | 31.39 | Analyst | medium |
| Own P/E history | 3Y | $359.94 | 11.5 | 31.39 | Analyst | medium |
| Peer P/FCF | 5Y | $1222.68 | 16.9 | 72.42 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $730.62 | 23.2 | 31.49 | Analyst | high |
| Peer P/S | 5Y | $289.37 | 1.1 | 269.87 | guidance | high |
| PEG | 5Y | $309.98 | 9.8 | 31.49 | Analyst | high |
| Own P/E history | 5Y | $361.20 | 11.5 | 31.49 | Analyst | high |